Olema Pharmaceuticals, Inc.
Clinical trials sponsored by Olema Pharmaceuticals, Inc., explained in plain language.
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control OngoingThis study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug duo takes on Hard-to-Treat breast cancer
Disease control OngoingThis early-stage trial tests a new drug called OP-1250 combined with an approved targeted therapy, palbociclib, in 60 adults with advanced or metastatic HR-positive, HER2-negative breast cancer. The goal is to find the safest dose and see if the combination can slow tumor growth.…
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC